Nath Bio-Genes Reports 19% Revenue Growth and Declares Dividend

Standalone Revenue: Rs 431.60 crore | Standalone Profit After Tax: Rs 44.43 crore
Reader Takeaway: Strong revenue expansion drives investor confidence, while proposed executive pay hikes remain a key point of discussion.

What just happened

Nath Bio-Genes (India) Ltd has released its notice for the 33rd Annual General Meeting (AGM), scheduled for September 24, 2026. Alongside the AGM notification, the company disclosed its financial performance for the fiscal year ended March 31, 2026. The board has proposed a final dividend of Rs 2 per equity share, representing a 20% payout on its face value of Rs 10, pending shareholder approval.

Why this matters

The company demonstrated healthy growth, with standalone revenue climbing to Rs 431.60 crore from Rs 362.31 crore in the previous fiscal year, a 19.12% year-on-year increase. PAT also showed a steady rise to Rs 44.43 crore compared to Rs 42.14 crore in FY 2024-25. The record date for the dividend eligibility is set for Friday, September 11, 2026.

Governance Updates

Significant corporate actions include a major revision in remuneration for Managing Director Mr. Satish Laxminarayan Kagliwal, proposed to increase from Rs 66 lakh per annum to Rs 1.44 crore effective January 1, 2026. The company is also seeking the re-appointment of Mrs. Jeevanlata Kagliwal as a director and Mr. Hitesh Rajnikant Purohit as an Independent Director for a second five-year term beginning March 2027.

What to track next

Investors should prepare for the e-voting process, which opens on September 21, 2026, and closes at 5:00 p.m. IST on September 23, 2026. Shareholders will vote on the proposed remuneration changes and the adoption of financial statements during the virtual AGM.